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ABSTRACT 31 
Background 32 
Yaws is a substantial cause of chronic disfiguring ulcers in children in at least 14 countries in the 33 
tropics. WHO’s newly adopted strategy for yaws eradication employs a single round of mass 34 
azithromycin treatment followed by targeted treatment programs, and data from pilot studies have 35 
shown a short-term significant reduction of yaws. We assessed the long-term efficacy of the WHO 36 
strategy for yaws eradication. 37 
 38 
Methods 39 
Between April 15, 2013, and Oct 24, 2016, we did a longitudinal study on a Papua New Guinea island 40 
(Lihir; 16092 population) in which yaws was endemic. In the initial study, the participants were 41 
followed for 12 months; in this extended follow-up study, clinical, serological, and PCR surveys were 42 
continued every 6 months for 42 months. We used genotyping and travel history to identify 43 
importation events. Active yaws confirmed by PCR specific for Treponema pallidum was the primary-44 
outcome indicator. This study is registered with ClinicalTrials.gov, number NCT01955252. 45 
 46 
Findings 47 
Mass azithromycin treatment (coverage rate of 84%) followed by targeted treatment programs 48 
reduced the prevalence of active yaws from 1·8% to a minimum of 0·1% at 18 months (difference 49 
from baseline, -1·7%, 95% CI, -1.9 to -1.4; P<0·0001), but the infection began to re-emerge after 24 50 
months with a significant increase to 0·4% at 42 months (difference from 18 months, 0·3%, 95% CI 51 
0.1 to 0.4; P<0·0001). At each time point after baseline, > 70% of the total community burden of 52 
yaws was found in persons who had not had the mass treatment or as new infections in non-53 
travelling residents. At months 36 and 42, five cases of active yaws, all from the same village, 54 
demonstrated clinical failure following azithromycin treatment, with PCR detected mutations in the 55 
23S ribosomal RNA genes conferring resistance to azithromycin. A sustained  decrease in the 56 
prevalence of high titre latent yaws from 13.7% to <1.5% in asymptomatic children aged 1–5 years 57 
old and of genetic diversity of yaws strains from 0·139 to  <0·046 between 24 and 42 months 58 
indicated a reduction in transmission of infection. 59 
 60 
Interpretation 61 
The implementation of the WHO strategy did not, in the long-term, achieve elimination in a high-62 
endemic community mainly due to the individuals who were absent at the time of mass treatment in 63 
whom yaws reactivated; repeated mass treatment might be necessary to eliminate yaws. To our 64 
knowledge this is the first report of the emergence of azithromycin-resistant T. p. pertenue and 65 
spread within one village. Communities’ surveillance should be strengthened to detect any possible 66 
treatment failure and biological markers of resistance. 67 
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Panel 1. Research in context 73 
Evidence before this study 74 
We searched PubMed on Feb 17, 2017 for studies published in English using the search terms 75 
“yaws”, “Treponema pallidum”, “mass treatment”, “azithromycin”, and “penicillin”. We searched for 76 
studies that assessed the efficacy of mass azithromycin treatment for yaws. Empirical data on the 77 
short-term impact of the WHO strategy became available after the start of this study; a single round 78 
of mass treatment in communities with high baseline infection rates in Ghana and Solomon Islands 79 
resulted in a significant decrease in prevalence of active and latent yaws at 12 and 18 months after 80 
treatment, respectively. The quality of the evidence was low, comprising primarily small sample size 81 
cross-sectional studies. Moreover, previous experience in the 1950s using mass treatment with 82 
penicillin and recent mathematical modelling suggested that, after an initial reduction, the disease 83 
may persist or rebound to pre-mass treatment amounts. 84 
 85 
Added value of this study 86 
To our knowledge, this is the first study to report the long-term efficacy of the modern WHO 87 
strategy for yaws eradication. We repeatedly examined a community of about 16,000 people and 88 
used PCR analysis specific to Treponema pallidum to determine the prevalence of active disease over 89 
42 months. Through this approach we were able to accurately measure the prevalence of active 90 
yaws and detect the appearance of macrolide-resistant strains. We used a novel genotyping method 91 
to determine temporal changes on genetic diversity of T. p. pertenue strains and to identify 92 
importation events. 93 
 94 
Implications of all the available evidence 95 
Active and latent yaws can be cured with single-dose azithromycin treatment and a single round of 96 
mass antibiotic treatment with coverage as high as 84% greatly reduces infection and transmission, 97 
but does not achieve complete and permanent reduction to zero new cases, with evidence of re-98 
emergence after 24 months. We suggest that yaws eradication policies should be revised with 99 
consideration of expansion to repeated 6-12 monthly mass treatments for at least two-three rounds. 100 
The data also suggest that azithromycin resistance in T. p. pertenue has emerged as a result of the 101 
program implementation, which reveals the need for effective drug resistance monitoring as part of 102 
yaws eradication programs to prevent spread of antibiotic-resistant strains.  103 
 104 
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INTRODUCTION 106 
The World Health Organization (WHO) has already begun implementing a program designed to 107 
eradicate yaws, an infectious disease caused by Treponema pallidum subsp. pertenue (T p pertenue). 108 
The global burden of yaws is substantial, with more than 89 million people living in yaws endemic 109 
areas and 100,000 annual reported cases of chronic ulcers or papilloma that are a major physical and 110 
psychological burden in young children. 111 
 112 
The cornerstone of the WHO’s strategy is the mass administration of azithromycin aiming for a 113 
population coverage of >90%.1 The drug is well-tolerated and very effective against yaws.2,3 It is 114 
given as one supervised dose, so compliance is assured. Treatment of all members of a yaws-115 
endemic community, irrespective of their clinical status, allows individuals harbouring the infection 116 
without any skin manifestation (latent infection) to be successfully exposed to curative doses of the 117 
treatment. Clearance of the pathogen responsible for yaws from individuals with active and latent 118 
infection, which constitute the infectious reservoir, has the potential to interrupt transmission.4 The 119 
WHO strategy calls for the use of PCR technology to confirm the diagnosis and to monitor the 120 
emergence of resistance to azithromycin after mass treatment.5 121 
 122 
A second important element of the WHO strategy to increase the effectiveness of yaws eradication 123 
programmes is to follow mass drug administration (MDA) with active case detection surveys every 3-124 
6 months, consisting of blanket screening to identify and treat all active yaws cases and their 125 
contacts (often called total targeted treatment).6 This second element aims to achieve elimination 126 
by early detection of existing (e.g. missed MDA), recurrent (e.g. relapse of untreated latent 127 
infections), or newly introduced (e.g. crossing regional borders) active yaws cases. A third element is 128 
a strengthened health and community system for surveillance and management of patients who 129 
present to health care between surveys.6 130 
 131 
We previously reported the effect of single-dose mass azithromycin treatment, with a coverage rate 132 
of 83·8%, on the prevalence of active and latent yaws 12 months after the intervention.7 MDA with 133 
azithromycin was associated with a nearly 90% reduction of serologically-confirmed active yaws 134 
from 2·4% to 0·3%. Single mass azithromycin treatment has also shown short-term efficacy in other 135 
clinical trials in Ghana (Aziz A, West Akim District Health Administration, Eastern Region, Ghana,  136 
personal communication) and Solomon Islands;8,9 however, the long-term efficacy of the WHO 137 
strategy has not yet been determined. 138 
 139 
We now report the results of 42 months of follow-up in our study communities to assess the long-140 
term effect of the WHO strategy to eradicate yaws.  141 
 142 
METHODS 143 
Study setting and participants 144 
Between April 15, 2013 and Oct 24, 2016, we did  a longitudinal study of yaws in the population of 145 
Lihir Island, New Ireland Province, Papua New Guinea. The characteristics of the area have been 146 
described in detail before.7 The climate is tropical with two distinct seasons: rainy and dry seasons. 147 
All villages of Lihir Island had a high prevalence of active yaws before MDA (range 0·5 to 3·8%).10  148 
 149 
We have previously reported the results of the first 12 months of follow up after MDA, in which the 150 
primary objective was to estimate the prevalence of clinically suspected yaws with serological 151 
confirmation of treponemal infection.7 All residents of Lihir Island have been followed during the 152 
extended phase of this study for an additional 30 months (months 12–42). Serological methods do 153 
not result in identification of all cases of active yaws because very early infection, while highly 154 
infectious, can be seronegative. By contrast, participants with latent yaws can present with skin 155 
ulcers caused by other bacteria (e.g. Haemophilus ducreyi) resulting in false-positive diagnoses of 156 
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active yaws.11-13 Consequently, throughout our study we incorporated molecular diagnostics as our 157 
case definition of active yaws. PCR testing of ulcers allowed us to more clearly delineate the effect of 158 
the intervention on participants with true active yaws (lesion PCR positive for T. pallidum) and on 159 
those participants with latent yaws and a different cause of the current skin infection (i.e. positive 160 
serology for treponemal infection but lesion PCR negative for T. pallidum). 161 
 162 
The initial MDA programme consisted of a centralized distribution where community members in 163 
each village gathered in a central location and received treatment, and compliance was recorded in 164 
treatment register books (ie, census list). After the initial MDA campaign,7 we did six monthly total 165 
targeted  surveys in accordance with the standards advocated by WHO. Before each survey, 166 
population sensitization was undertaken to inform village authorities of the program. Villages were 167 
visited by a mobile team of health-care workers that first screened the village schools to examine 168 
children, and then did house-to-house screening. All subjects with skin ulcers and their contacts 169 
(household, frequent family friends, schoolmates, and playmates) were treated with directly 170 
observed single-dose azithromycin (30 mg/Kg) procured by WHO from Medopharm (Chennai, India). 171 
To simplify the treatment in the field, dosing charts were used to guide the participants’ age-based 172 
dose. Individuals were observed for 30 minutes following treatment; if vomiting occurred within this 173 
time period, the child was retreated. Treatment was provided without cost to participants. Clinical 174 
follow-up examinations were conducted 2 weeks after any treatment to identify potential treatment 175 
failures. All field workers and clinical and laboratory staff involved in the follow-up of study 176 
participants remained masked to previous individual-specific and village-specific results. 177 
 178 
All participants, or their parents, provided oral informed consent for screening. In addition, we 179 
obtained written informed consent from parents or guardians, as well as verbal agreement of the 180 
children with clinically suspected yaws before enrolment in ulcer aetiology studies and serological 181 
surveys. The protocol was approved by the National Medical Research Advisory Committee of the 182 
PNG Ministry of Health (MRAC no 12·36). The study is registered with ClinicalTrials.gov, number 183 
NTC01955252. 184 
 185 
Procedures 186 
Clinical surveys were undertaken in the entire resident population present at the time of the visits 187 
for assessment of clinical signs and symptoms of active yaws at study months 18, 24, 30, 36, and 42. 188 
We used tally sheets to record the number of people examined at total targerted treatment surveys 189 
and a standardized form to record data of patients with suspected lesions. Specimens were collected 190 
from the largest lesion of all subjects with ulcers or papillomas using dacron swabs (FITZCO Inc, 191 
Minneapolis, MN, USA) that were vigorously rotated across a 1 cm2 area and then placed into a tube 192 
containing transport medium as previously described.7 At the baseline and 6-month surveys we 193 
swabbe a systematic random sample of 90 and 84 ulcers. The specimens were forwarded to the 194 
University of Washington laboratory (Seattle, WA, USA) for PCR testing. The number of active yaws 195 
cases in the entire population was estimated using the proportion of PCR-positive specimens among 196 
the subset of PCR-tested lesions multiplied by the total number of detected lesions. In 12-month to 197 
42-month surveys, we swabbed to test all ulcers detected; therefore we obtained a direct 198 
measurement of the number of yaws cases in the entire population.  199 
 200 
Laboratory methods used to confirm yaws and to detect macrolide-resistance mutations have been 201 
previously described.11,14 In short, three T. pallidum gene targets, tp0548, tpN47 (tp0574), and a 202 
pertenue-specific region of the tprL (tp1031) gene were PCR amplified to detect the presence of T. 203 
pallidum DNA and to confirm the subspecies. We used previously described restriction fragment 204 
length polymorphism methods to detect A2058G14 and A2059G15 point mutations in both copies of 205 
the 23S ribosomal RNA genes. We did strain genotyping by sequencing a panel of three molecular 206 
markers (tp0548, tp0136 and tp0326)16 to determine the genetic diversity of T. p. pertenue 207 
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infections and to identify importation events. The aggregated molecular typing of strains causing 208 
incident infection in Lihir Island has been reported in a paper16 detailing the development of the 209 
typing system. 210 
 211 
Significant reductions in transmission intensity are required to reduce the diversity of bacterial 212 
populations; hence we used genetic diversity as a marker for transmission. We used PCR targeting 213 
the 16S rRNA gene to identify H. ducreyi.17 Participants with lesions underwent serological testing 214 
using both qualitative Rapid Plasma Reagin (RPR) and T. pallidum haemagglutination assay (TPHA); 215 
specimens which tested dually positive were analysed with the quantitative RPR. 216 
 217 
Demographic and epidemiologic data were systematically collected for every case of ulcer detected. 218 
Compliance with yaws MDA therapy was assessed by self-reported data and verified using the 219 
treatment register books for MDA (ie, census lists). Travel history was assessed by self-reported 220 
travel out of Lihir Island to a yaws endemic area in the preceding 6 months, regardless of compliance 221 
to MDA. History of in-migration was assessed by self-reported migration to Lihir Island in the 222 
preceding 6 months and verified by non-appearance at the previous year census, regardless of 223 
compliance to MDA. 224 
 225 
Serological surveys to detect latent yaws in a subgroup of asymptomatic children 1–15 years old 226 
were done at months 18, 24, 30, 36, and 42 after MDA. We selected six villages using computer-227 
generated random numbers, and all children within the age group were recruited for inclusion. We 228 
regenerated the random sample at each survey; therefore different villages may have been selected 229 
for testing in different rounds. Venous blood samples were collected from assenting children for 230 
TPHA and qualitative and quantitative RPR testing. 231 
 232 
Outcomes and statistical analysis 233 
The primary outcome indicator to assess the prevalence of infection was the frequency of 234 
participants with active yaws lesions confirmed by PCR (regardless of their serology result), which 235 
was assessed by examining everyone in the population. Secondary outcome indicators included 236 
prevalence of participants with an ulcer who were serologically positive (regardless of PCR result). To 237 
control for potential confounders of infection persistence we looked at the proportion of post-MDA 238 
new incident yaws cases that had missed MDA therapy, the proportion of yaws cases that originated 239 
from travel versus local residual source according to travel history and genotyping results, and the 240 
proportion of yaws samples with genetic mutations associated with macrolide resistance at each 241 
timepoint. Secondary outcome indicators that were used to assess onward transmission of infection 242 
were the prevalence of latent yaws with high-titre seroreactivity (RPR ≥1:16) in a subset of children 243 
aged 1-5 years old in villages selected using computer generated random numbers, and the genetic 244 
diversity of T. p. pertenue isolates from active yaws lesions. 245 
 246 
We estimated the prevalence ratiofor comparison of active yaws at seven time-points using a log-247 
binomial regression model. The model accounted for the uncertainty in the estimate of number of 248 
active yaws cases at baseline. We estimated the adjusted prevalence ratio of high-titre latent yaws 249 
using the cluster option in the models to account for the variability between clusters selected for 250 
serosurveys. Analyses were done using Stata (version 13·1). To measure the genetic diversity of T. p. 251 
pertenue isolates at each round we estimated the Mean Evolutionary Diversity by calculating the 252 
number of base substitutions per site for each round using the Kimura 2 parameter model in MEGA 253 
(version 7).18 We determined significant differences among years using one-way ANOVA. 254 
 255 
We initially calculated that a sample size of 1000 children would be needed at 24-42 months to 256 
estimate the prevalence of high-titre latent yaws with a precision of 0·83%, at a two-sided 257 
significance level of 5% in a finite population of 6600 children 1-15 years old. We assumed that the 258 
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prevalence of latent yaws at 24-42 months would be 2%. However, we adjusted the sample size to 259 
reduce survey fatigue by the survey team and to minimize venipuncture of children; the revised 260 
calculations indicated that 500 children was enough to estimate prevalence with a precision of 261 
1·18%.  262 
 263 
RESULTS 264 
The study population lives in the 28 villages of Lihir Island; in small subsistence farming communities 265 
with a mean population of 575 (SD 225) people per village. At baseline 16,092 people lived in the 266 
area, and a total of 13,490 individuals (83·8%) received single-dose azithromycin (or benzathine 267 
benzylpenicillin if azithromycin was contraindicated). Total population size remained fairly stable 268 
throughout the study, and a mean proportion of 79·0% (SD 8·2) of the population was examined at 269 
each survey (Table 1). Some individuals could not be reached at scheduled visit times (e.g. children 270 
were absent from school, adults were working in the fields, families had moved away on temporary 271 
or permanent basis).  272 
The overall prevalence of active yaws fell from an estimated 1·8% before MDA to a minimum of 0·1% 273 
at 18 months (difference from baseline, -1·7%; 95%CI, -1·9 to -1·4; P<0·0001), but began to re-274 
emerge from 30 months onwards (table 1). The prevalence increased to 0·4% at 42 months 275 
(difference from 18 months, 0·3%; 95%CI, 0·1 to 0·4; P<0·0001), with a major rise from 36 to 42 276 
months (table 1). Similarly, the prevalence of participants with clinically suspected yaws lesions and 277 
positive serological findings fell initially, but the prevalence appeared to increaseby month 30 (table 278 
1). We noted anincrease from a minimum of 0·2% at 24 months to 0·5% at 42 months (difference, 279 
0·3%; 95CI, 0·1 to 0·4; P<0·0001).  280 
 281 
Overall, 239 participants were PCR positive for T. pallidum throughout the study, including 31 (13%) 282 
at baseline and 208 (87%) in total in the period after MDA. At each survey after MDA, between 36% 283 
and 61% of the community burden of newly identified active yaws were accounted for by non-284 
travelling residents who had been absent at initial mass treatment visit (figure-1). Non-travelling 285 
residents who were present at MDA ranged from 27% to 53%, and migrants and residents who had 286 
travelled to a yaws endemic area after MDA represented 28% of cases at each timepoint (figure 1).  287 
 288 
We report  the temporal variation of the genetic diversity over the 42-month study (figure 1). At 289 
baseline, three molecular types were identified, with strain JG8 accounting for ten (58·8%) of 17 fully 290 
typable samples (figure 1).  Over time, molecular type diversity was reduced to zero (only one 291 
genotype –JG8– was present) at 24 months which represented a reduction of the mean evolutionary 292 
diversity of T. p. pertenue from 0·139 to 0·000 (P<0·0001; figure 1). Diversity remained low (<0.046) 293 
thereafter (figure 1). After 24 months, strain JG8 caused all 76 new incident cases of yaws in non-294 
travelling patients with typable samples, and 18 (72%) of 25 cases in travelling patients. The 295 
remaining seven cases (28%) who had a history of travel or migration were infected with genotypes 296 
SE7 or SD6, which supports that these cases were imported and not derived from a local source.  297 
 298 
When we looked at the proportion of participants with a history of travel according to genotypes 299 
(table 2), all TD6, TG6, and JD8, as well as 84% of JG8 specimens were seen in patients who had not 300 
travelled; all SD6 and TG8 strains, and 82% of SE7 occurred in patients who travelled or migrated. 301 
 302 
Of 31 active yaws cases tested at baseline, the 23S rRNA gene could be amplified by PCR in 24 cases 303 
(77%); all had wild type 23S rRNA sequence at positions 2058 and 2059 (figure 1). Of 208 PCR-304 
confirmed cases of active yaws in the period after MDA, the 23S rRNA gene could be amplified by 305 
PCR in 186 (89%), of which 181 (97%) had wild-type strains, but two cases (1%) at 36 months and 306 
three cases (2%) at 42 months revealed A2059G mutations associated with macrolide-resistance. 307 
The five samples had A2059G mutations in both of the 23S rRNA loci (figure 1). 308 
 309 
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The index case was an 11-year old boy who was diagnosed with active yaws at the 30-month survey 310 
(lesional swab was PCR-positive for T. p. pertenue with wild-type 23S rRNA),treated with a full dose 311 
of azithromycin 1.5 g without vomiting the medication, and shower clinical improvement 2 weeks 312 
after medication (figure 2). The patient was seen 6 months later with recurrent papillomatous 313 
lesions (figure 2) and serological treatment failure. The skin biopsy of these lesions showed 314 
abundant spirochetes (figure 2 ) and T. p. pertenue containing the 23S rRNA A2059G macrolide 315 
resistance mutation was identified by PCR. The patient was treated with 2.4 MUI of benzathine 316 
benzylpenicillin and showed clinical cure after 2 weeks and serological cure after 6 months. 317 
 318 
The other four cases of antibiotic-resistant infection, diagnosed at 36 months (one case) and 42 319 
months (three cases), were 9-14 year old boys who lived in the same village as the index case 320 
(related to or friends of the index case); they had not travelled outside the village. All of them 321 
reported no oral antibiotic-treatment other than that received during MDA. All presented with 322 
worsening skin lesions 2-weeks after azithromycin treatment and were subsequently treated with 323 
benzathine benzylpenicillin, according to age (1.2 MU for <10 years old and 2.4 MU for ≥10 years 324 
old).  All strains with A2059G mutations were molecular type JG8, the most common type on Lihir 325 
Island. 326 
The prevalence of high titre latent yaws in children aged 1–5 years fell from 14% before MDA to 1% 327 
at 12 months (P=0·0005)7 and remained lower than 2% at each timepoint thereafter. No participant 328 
aged 1-5 years of age had high titre latent yaws infection at 30 or 42 months (Table 3). Decreases in 329 
this index were also observed in the older age group of 6–15 years. The decrease from baseline to 12 330 
months was significant (P<0·0001). 7 At 18, 24, 36, and 42 months, the prevalence of high titre latent 331 
yaws infection remained significantly lower that it had been before mass treatment, although in 332 
each instance it was not significantly below that recorded for the previous round (table 3). 333 
 334 
Regarding the proportion of ulcers due to T. p. pertenue and H. ducreyi, the baseline and 12 months  335 
after treatment results for PCR in detecting the causal agents have been previously described.7 The 336 
proportion of subjects that had detectable T. p. pertenue DNA (either alone or co-infection with H. 337 
ducreyi) was lower at 12 (p=0.0030), 18 (p=0.023), and 24 (p=0.033) than it had been at baseline, but 338 
it increased to a similar proportion as baseline by month 30 (p=0.176; appendix);although, the 339 
overall prevalence of lesions remained much lower than baseline. The proportion of ulcers due to H. 340 
ducreyi remained relatively stable during the 42 months of follow up (appendix). 341 
 342 
DISCUSSION 343 
In our study, we found that one mass administration of antibiotics followed by targeted treatment of 344 
symptomatic cases and their contacts caused a transient sharp decline on infection levels and 345 
transmission, but did not eliminate yaws in a highly endemic island community. To our knowledge, 346 
this is the largest studythat evaluates a yaws eradication program with oral antibiotics and with a 347 
long, 42-month follow-up. The initial impact of a single-dose treatment with oral azithromycin was a 348 
large reduction in prevalence of active yaws, similar to the findings subsequently described for 349 
Ghana and Solomon Islands.8-9 The maximum impact of the intervention in this study was observed 350 
by the end of the second year, but thereafter the overall prevalence of yaws increased with many 351 
children presenting active yaws lesions in all villages. When we did molecular typing of T. p. pertenue 352 
samples from Lihir, we found a great reduction in genetic diversity of the circulating strains over 353 
time, which reached a minimum at 24 months when only one genotype was present. A reduction in 354 
genetic diversity and in seroreactivity of children 1-5 years old indicated an overall reduction in 355 
transmission, and hence the susceptibility of the bacteria population to the MDA intervention.  356 
 357 
The relapse of untreated latent infections was the most important factor that hindered elimination 358 
efforts in this community, along with, to a lesser extent, the reintroduction of yaws throughcases of 359 
in-migration. Almost half of the individuals with new infections at follow-up surveys had not been 360 
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present for MDA. Although we had not evaluated baseline serostatus for these children (because it 361 
was impractical and impossible for financial reasons to assess the baseline serrostatus of everyone 362 
on the entire island), given the high prevalence of seropositivity of about 30% in randomly selected 363 
children at baseline, the active yaws episode was likely to be due to relapsed latent yaws. This 364 
finding is significant because it highlights the importance of achieving high initial treatment coverage 365 
of all persons to be sure of treating latent cases. Results of studies done in the 1950s indicate that 366 
because of the tendency of latent yaws to relapse early in the course of untreated infection, it is 367 
critical to treat latent infections as part of eradication efforts.19-21 In addition, results of a 368 
mathematical model predict that >65% coverage of latent cases is required during each total 369 
targeted treatment program to achieve eradication;22 however, contact tracingis unlikely to detect 370 
this proportion of latently infected individuals. Given the high coverage requirements for latent 371 
cases, and the relatively high fixed-costs of reaching endemic communities when compared to the 372 
relatively low costs of generic azithromycin, doing multiple rounds of MDA before the switch to total 373 
targeted treatment may be prefereable. Determination of the optimal number of MDA rounds to 374 
achieve eradication, the best intervals between rounds, and suitable interventions to prevent 375 
repeated non-attendance at MDA will require careful examination. 376 
 377 
Importantly, we report the first documented macrolide resistance in T. p. pertenue infections. 378 
Analysis of five clinical specimens from 208 samples tested during the 42 month period after MDA, 379 
showed a T. p. pertenue strain carrying the 23S rRNA A2059G point mutation. We speculate that the 380 
first case likely to have had a de novo drug resistance mutation; antibiotic pressure has been 381 
associated with selection of mutants in syphilis studies.23 A direct epidemiological association was 382 
present among all patients who had macrolide-resistant yaws suggesting that all had been infected 383 
with a single macrolide-resistant strain resulting from direct transmission by the index case; hence 384 
there was local spread of the resistant clone. The selection of the resistance mutation is likely to be a 385 
result of the yaws eradication programme implementation because azithromycin was used in these 386 
communities (after MDA) only for targeted treatment of yaws and to treat urethritis and genital 387 
ulcer disease in adults. For the syphilis agent, Treponema pallidum subsp. pallidum, the increase in 388 
prevalence of macrolide resistant strains has been rapid up to 64-100% in some developed 389 
countries.24-28 However, whether this increase in prevalence is due to de novo point mutations or 390 
spread of a resistant strain, or both, is unclear. 14 In syphilis, macrolide-resistance mutations have 391 
been found in many different molecular strain types, consistent with de novo mutation. The 392 
frequency of emergence of primary resistance is proposed to be low because T. pallidum has two 393 
copies of the 23s rRNA gene and mutations in both operons seem to be required;29 in all five mutant 394 
samples from our study, the same mutation A2059G, was found in both copies of the 23S rRNA 395 
gene. However, Treponema denticola (a related spirochete) can have phenotypic resistance with a 396 
mutation in only a single allele.30 The role of dissemination of a single resistant strain in increased 397 
prevalence is not well defined for syphilis, as network analyses have not been performed. For yaws, 398 
travel of individuals is restricted in endemic countries, and the risk of spread from one country to 399 
another may be minimal. Emergence of macrolide-resistant strains, however, might cause local 400 
outbreaks. 401 
 402 
The strengths of this study are the use of PCR to conclusively diagnose active yaws and the use of 403 
genotyping to differentiate between indigenous and imported cases. Additionally, the clinical 404 
surveys involved the entire population of interest, which is important to accurately measure a 405 
reduction of infection levels to zero because of the focal nature of the disease. A limitation of this 406 
study is the sampling of ulcers for PCR testing used in the first two rounds. Our aim was to swab a 407 
systematic sample of all observed ulcers, but this approach was not fully implemented in all villages. 408 
However, we believe that any association that might exist between the probability that an ulcer was 409 
swabbed and the probability that an ulcer was PCR positive is slight enough that it would not 410 
compromise the conclusions of the paper. Another limitation is the smaller than anticipated sample 411 
10 
size in latent infection surveys. This might have reduced the power of our study to show definitively 412 
whether transmission of yaws had ceased (i.e. infection in children 1-5 years indicates recent 413 
infection). However, the finding of zero cases of high titre latent yaws in repeated surveys, together 414 
with results showing an overall reduced genetic diversity of strains causing active yaws, strongly 415 
indicates that transmission was largely interrupted.  416 
 417 
The generalizability of our findings is subject to three factors. First, rural Papua New Guinea might 418 
differ from other high-endemic zones in important environmental or cultural characteristics; 419 
however most yaws is found in rural tropical settings. Second, the impact of importation of infection 420 
could be larger in communities that are geographically contiguous to neighbouring areas where the 421 
disease is also endemic than in isolated island communities. Third, if the high coverage we achieved 422 
in MDA and subsequent total targeted treatment programs cannot be attained, as might be the case 423 
outside a research setting, re-emergence of disease could happen more rapidly. 424 
 425 
Our findings have substantial implications for the scalability of yaws eradication programs 426 
internationally and support the following adaptations to the current WHO strategy. First, a 427 
considerable effort to achieve coverage rates >90% should be the goal in the first round of 428 
treatment.  Second, distribution of a second or third round of azithromycin at 6-12 months intervals 429 
might be of substantial benefit. Third, efforts to eradicate yaws should aim to treat much broader 430 
geographical areas, especially in regions with substantial migration. Finally, clinical and biological 431 
surveillance needs to immediately detect drug resistance through the strengthening of capacities of 432 
laboratory networks in endemic countries. Because the identified macrolide resistance mutations 433 
appear to cause no fitness disadvantage in T. pallidum, resistant strains would likely persist in 434 
communities even in the absence of antibiotic pressure. Therefore, communities where significant 435 
resistance is identified will need guidelines for clinical and operational management of macrolide 436 
resistant yaws with benzathine benzylpenicillin treatment to achieve cure and to avoid 437 
dissemination of resistant strains.  438 
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FIGURE LEGENDS 
Figure 1. Characteristics of PCR-confirmed active yaws by epidemiological history, molecular type, and macrolide resistance mutation. 
PCR-confirmed active yaws refers to samples with positive results in either tpN47 (tp0574) or tp0548, and in which the pertenue subspecies was confirmed 
by TprL PCR amplicon size. T p pertenue=Treponema pallidum subspecies pertenue. MDA=mass drug administration. 
 
*A systematic random sample of 90 ([13%] out of 690) clinically suspected yaws cases at baseline and 84 ([69%]out of 121) at 6 months were tested by PCR; 
we provide data on the characteristics of lesions that were PCR-positive among the subset of PCR-tested lesions (31 at baseline and 41 at 6-months). In 
surveys between months 12 and 42, we tested all clinically suspected lesions by PCR; therefore we provide data on the characteristics of all lesions detected 
for these timepoints.  
†Not all T. p. pertenue positive samples could be fully typed for all three typing targets. 
§ P<0.0001 for the estimate of the mean evolutionary diversity of T. p. pertenue isolates at 24-month survey compared with baseline. 
¶ Data are the mean evolutionary diversity of T. p. pertenue isolates at each round. 
‡Not all T. p. pertenue positive samples could be amplified for 23S rRNA by PCR. 
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Figure 2.  Yaws lesions in a patient with treatment failure associated with macrolide-resistant 
Treponema pallidum subsp. pertenue.  
(A) Primary lesion (red, moist 2·5 cm ulcer) on the left leg of an 11-year-old patient with yaws 
observed at the 30 months survey. Lesional swab PCR was positive for T. p. pertenue with wild-type 
23S rRNA. (B) Secondary yaws papillomas (multiple nodules with yellow-colour granular surface) 
seen at 36 months survey. These lesions were PCR positive for T. p. pertenue with A2059G mutation 
in 23SrRNA. (C) Photomicrograph of skin biopsy of the larger papilloma lesion in Panel B with 
abundant spirochete organisms stained bright red by the Treponema pallidum immunohistochemical 
stain (×400 magnification).
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Table 1: Prevalence of skin ulcers and active yaws 
Time post 
MDA  
People in 
census 
People 
examined 
All Clinically Suspected Lesions Active Yaws Lesions*  
Clinically Suspected Lesions with 
Positive Serological Findings  
      
No. of cases 
(%) 
Prevalence ratio 
(95%CI) †‡ 
No. of 
cases (%) 
Prevalence ratio 
(95%CI) †‡ 
No. of cases 
(%)  
Prevalence ratio 
(95%CI)†‡ 
Baseline 16,092 13,490 (84%) 690 (5·1) 1 238 (1·8) § 1 323 (2·4) 1 
6 mo. 16,092 13,166 (82%) 121 (0·9) 0·18 (0·15; 0·22) 59 (0·4) ¶ 0·25 (0·19; 0·34) 44 (0·3) 0·14 (0·10; 0·19) 
12 mo. 17,339 13,204 (76%) 114 (0·9) 0·17 (0·14; 0·21) 19 (0·1) ǁ 0·08 (0·05; 0·13) 34 (0·3) 0·11 (0·08; 0·15) 
18 mo. 17,339 15,977 (92%) 88 (0·6) 0·11 ( 0·09; 0·13) 17 (0·1) ǁ 0·06 (0·04; 0·10) 38 (0·2) 0·10 (0·07; 0·14) 
24 mo. 17,555 11,792 (67%) 68 (0·6) 0·11 (0·09; 0·14) 13 (0·1) ǁ 0·06 (0·04; 0·11) 24 (0·2) 0·09 (0·06; 0·13) 
30 mo. 17,555 14,935 (85%) 120 (0·8) 0·16 (0·13; 0·19) 31 (0·2) ǁ 0·12 (0·08; 0·17) 52 (0·3) 0·15 (0·11; 0·19) 
36 mo. 18,836 14,765 (78%) 107 (0·7) 0·14 ( 0·12; 0.17) 36 (0·2) ǁ 0·14 (0·10; 0·20) 53 (0·4) 0·15 (0·11; 0·20) 
42 mo. 18,836 13,601 (72%) 107 (0·8) 0·15 ( 0·13; 0.19) 51 (0·4) ǁ 0·21 (0·16; 0·29) 63 (0·5) 0·19 (0·15; 0·25) 
*Active yaws refers to the estimated number of participants with lesional PCR positive results in either tpN47 (tp0574) or tp0548, and in which the 
pertenue subspecies was confirmed by TprL PCR amplicon size. 
†The prevalence ratio was calculated by means of the log-binomial model. The baseline prevalence is the reference value.  
‡ P<0.0001 for the significance of the model overall. 
§ At baseline, a random sample of 90 (out of 690) clinically suspected yaws lesions were tested by PCR; the number of active yaws cases in the entire 
population were estimated using the proportion of PCR-positive specimens among the subset of PCR-tested lesions (34·4% [31/90]) multiplied by the total 
number of clinically suspected yaws lesions detected (n 690).  
¶ At 6 months, the same approach as taken for baseline was used to estimate the number of active yaws cases. The proportion of PCR-positive specimens 
(48·8% [41/84]) was multiplied by the total number of clinically suspected yaws lesions detected (n 121). 
ǁ In 12-month to 42-month surveys, we tested all clinically suspicious lesions by PCR; therefore we obtained a direct measurement of the number of active 
yaws cases in the entire population.  
Baseline, 6, and 12 month data were previously published (Ref. 7) and are included here for comparison to later time points. 
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Table 2. Proportion of non-travelling vs travelling participants with yaws in the post-MDA period according to genotypes 
 
 
Genotypes of yaws strains 
Not fully typed 
cases (n=31) 
Total 
(n=208) 
JG8 (n=149) SE7 (n=11) TG8 (n=1) TD6 (n=11) TG6 (n=3) SD6 (n=1) JD8 (n=1) 
 
 
Non-travelling resident* 125 (83·9%) 2 (18·2%) 0 (0·0%) 11 (100%) 3 (100%) 0 (0·0%) 1 (100%) 26 (83·9%) 168 (80·8%) 
Travelling or in-migrated 
participant† 
24 (16·1%) 9 (81·8%) 1 (100%) 0 (0·0%) 0 (0·0%) 1 (100%) 0 (0·0%) 5 (16·1%) 40 (19.2%) 
*All non-travelling residents either absent or present at Mass Drug Administration.  
†Travel history was assessed by self-reported travel out of Lihir Island to a yaws endemic area in the preceding 6 months, regardless of compliance to MDA. 
History of in-migration was assessed by self-reported migration to Lihir Island in the preceding 6 months and verified by non-appearance at the previous 
year census, regardless of compliance to MDA. 
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Table 3.  Prevalence of latent yaws in subgroups determined by age 
 Time 
(month) 
Children aged 1 – 5 years Children aged 6 – 15 years 
No. of 
children 
tested 
All Cases of Latent Yaws*  High-titre Latent Yaws† 
No. of 
children 
tested 
All Cases of Latent Yaws*   High-titre Latent Yaws† 
     
Children 
(%) 
Adjusted 
prevalence ratio 
(95%CI)‡§ 
Children 
(%) 
Adjusted 
prevalence ratio 
(95%CI)‡¶ 
  
Children 
(%) 
Adjusted 
prevalence ratio 
(95%CI)‡ ǁ‖‖‖ 
Children 
(%) 
Adjusted 
prevalence ratio 
(95%CI)‡**‖ 
Baseline 117 26 (22·2) 1 16 (13·7) 1 874 299 (34·2) 1 165 (18·9) 1 
6 mo 77 10 (13·0) 0·58 (0·20; 1·74) 6 (7·8) 0·57 (0·15; 2·19) 797 251 (31·5) 0·92 (0·55; 1·53) 117 (14·7) 0·78 (0·40; 1·53) 
12 mo 114 6 (5·3) 0·24 (0·09; 0·63) 1 (0·9) 0·06 (0·01; 0·48) 796 143 (18·0) 0·53 (0·35; 0·79) 58 (7·3) 0·39 (0·19; 0·77) 
18 mo 81 9 (11·1) 0·50 (0·22; 1·12) 1 (1·2) 0·09 (0·02; 0·52) 462 129 (27·9) 0·82 (0·55; 1·22) 50 (10·8) 0·57 (0·34; 0·98) 
24 mo 69 6 (8·7) 0·39 (0·17; 0·88) 1 (1·4) 0·11 (0·01; 0·75) 445 113 (25·4) 0·74 (0·48; 1·15) 24 (5·4) 0·29 (0·16; 0·52) 
30 mo 65 4 (6·2) 0·28 (0·10; 0·79) 0 (0·0) -- 416 136 (32·7) 0·96 (0·62; 1·48) 33 (7·9) 0·42 (0·18; 0·97) 
36 mo 66 3 (4·5) 0·20 (0·05; 0·80) 1 (1·5) 0·11 (0·02; 0·78) 470 130 (27·7) 0·81 (0·47; 1·40) 22 (4·7) 0·25 (0·08; 0·81) 
42mo. 68 6 (8·8) 0·40 (0·17; 0·94) 0 (0·0) -- 422 84 (19·9) 0·58 (0·37; 0·91) 28 (6·6) 0·35 (0·20; 0·62) 
* The analysis included all seropositive children with a reactive TPHA and RPR titre of at least 1:2. 
† The analysis included children with a reactive TPHA and RPR titre of at least 1:16. 
‡ The adjusted prevalence ratio was calculated with the use of the cluster option of a log-binomial regression model. The baseline prevalence is the 
reference value.  
For the significance of the overall model § P = 0·0165, ¶ P = 0·0014, ǁ P = 0·0024, ** P = 0·0002. 
Baseline, 6 and 12 month data were previously published (Ref. 7) and are included here for comparison to later time points 
  
4 
Extended data Table 1: Aetiology of skin ulcers prior to MDA of azithromycin and in subsequent rounds of targeted treatment *† 
 Time (month) 
Participants 
tested for PCR 
Treponema 
pallidum 
subsp. 
pertenue 
only detected 
Both T. p. 
pertenue and 
H. ducreyi 
detected 
Haemophilus 
ducreyi 
only detected 
Negative 
for T. pallidum  
and H. ducreyi 
 no. no. of participants (%) 
Baseline 90* 19 (21·1) 12 (13·3) 42 (46·7) 17 (18·9) 
6 mo. 84* 14 (16·7) 27 (32·1) 32 (38·1) 11 (13·1) 
12 mo. 114 12 (10·5) 7 (6·1) 53 (46·5) 42 (36·8) 
18 mo. 88 12 (13·6) 5 (5·7) 35 (39·8) 36 (40·9) 
24 mo. 68 6 (8·8) 7 (10·3) 28 (41·2) 27 (39·7) 
30 mo. 120 19 (15·8) 12 (10·0) 63 (52·5) 26 (21·7) 
36 mo. 107 24 (22·4) 12 (11·2) 49 (45·8) 22 (20·6) 
42mo. 107 37 (34·6) 14 (13·1) 30 (28·0) 26 (24·3) 
* Data of PCR-confirmed yaws cases for baseline and 6 months represent a random sample of 90 and 84 ulcers that were tested by PCR from a total of 690 
and 121 participants with skin ulcers detected, respectively. Data from 12 months to 42 months represent all ulcers detected.  
† P<0.0001 by the chi-square test for the between-group comparison within each type of infection. 
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